Sign up USA
Proactive Investors - Run By Investors For Investors

Valeant gains on raising $2 billion in stock offering

Valeant gains on raising $2 billion in stock offering

Valeant Pharmaceuticals International Inc. (TSE:VRX), Canada’s largest drug-maker, advanced as much as 2 percent on Wednesday after saying it raised about $2 billion in an offering of common shares priced at $85 a share. 

The shares rose to as high as C$87.55 before trading at C$86.44, up 0.7 percent at 3:40 p.m. in Toronto, stretching this year’s gains to approximately 45 percent.

The Laval, Quebec-based company said in a statement late on Tuesday that it will use the proceeds to help fund its planned $8.7 billion acquisition of global eye-care company Bausch & Lomb Holdings Inc. The stock offering is expected to close by Monday.

The Bausch & Lomb acquisition is expected to close in the third quarter. Valeant had about 305.9 million shares outstanding as of April 30.

Meanwhile on Wednesday, Bloomberg News cited unidentified people as saying Valeant is seeking a $3.55 billion term loan B and a $500 million term A piece to support its purchase of Bausch.

 

 



Register here to be notified of future VRX Company articles
View full VRX profile

Valeant Pharmaceuticals Timeline

Related Articles

Harley Street London street sign
Fri
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
shutterstock_184785974.jpg
April 28 2016
Last year's acquisition of Kinesis Pharma meant that it could now offer a one-stop shop for its pharmaceuticals clients and expand its client base.
AZN2.jpg
March 31 2016
Amryt Pharmaceuticals will join the London market in a deal that values it at £29.6mln. A share placing, meanwhile, will bring in £10mln to be used to develop the company’s lead treatment for a rare skin disorder.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC